cells

Quemliclustat

Quemliclustat (AB680): A POTENT AND SELECTIVE SMALL MOLECULE INHIBITOR OF CD73

CD73 is the primary enzymatic producer of immunosuppressive adenosine in the tumor microenvironment, and high CD73 expression is associated with significantly poorer prognosis in several tumor types.

Quemliclustat CLINICAL TRIALS

Castration-resistant prostate cancer (ARC-6)

A Phase 1b/2 trial to evaluate the efficacy and safety of etrumadenant-based treatment combinations in participants with metastatic castration-resistant prostate cancer.

Pancreatic adenocarcinoma (ARC-8)

A Phase 1 trial to evaluate the safety, tolerability, PD, PK, and clinical activity of quemil + zimberelimab + nab-paclitaxel + gemcitabine in participants with advanced pancreatic cancer.